Testing an experimental treatment for moderate to severe Crohn's disease
Treatments studied
Part of Digestive system, Pain clinical trials.
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You weigh at least 40 kg (about 88 lbs).
- You have been diagnosed with Crohn's disease for at least one year, with active inflammation confirmed by a colonoscopy.
- Your Crohn's disease is moderate to severe and has not improved after trying two or more advanced treatments like TNF-inhibitors, IL-12/23 inhibitors, anti-integrins, or JAK inhibitors.
- You are not currently taking more than 20 mg of prednisone (or equivalent) per day, or more than 9 mg of budesonide per day.
- You do not have any uncontrolled infections, HIV, active hepatitis B or C, or untreated tuberculosis.
- You do not have certain Crohn's complications like active fistulas, abscesses, strictures that cannot be dilated, or a prior organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
This study follows children newly diagnosed with Crohn’s disease to see how results from scans and endoscopy (camera scope) relate to outcomes over the first year. It may help doctors choose better early treatment plans and monitor children more effectively.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.